Free PSA Test Awarded US Patent
ABBOTT PARK, Ill--Abbott Laboratories and the Finnish-based company Wallac Oy, a subsidiary of EG&G Inc. (Wellesley, Mass), have received a US patent for two methods of assaying free PSA (prostate-specific antigen).
ABBOTT PARK, Ill--Abbott Laboratories and the Finnish-based companyWallac Oy, a subsidiary of EG&G Inc. (Wellesley, Mass), havereceived a US patent for two methods of assaying free PSA (prostate-specificantigen).
The patent was issued to two inventors, Dr. Ulf-Hakan Stenman,of Helsinki University Central Hospital, and Dr. Hans Lilja, ofLund University.
The inventors gave exclusive rights to Wallac, which subsequentlygranted a sublicense to Abbott. The patent covers immmunoassaysfor free PSA and the use of the ratio of free-to-total PSA tobetter distinguish between prostate cancer and benign prostatichyperplasia (BPH).
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
